Moderna Financial Statements From 2010 to 2025
| 0QF Stock | EUR 31.82 0.34 1.08% |
Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna's main balance sheet or income statement drivers, such as , as well as many indicators such as . Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules.
Moderna |
Moderna Company Current Valuation Analysis
Moderna's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Moderna Current Valuation | 69.44 B |
Most of Moderna's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moderna is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Moderna has a Current Valuation of 69.44 B. This is 383.44% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all Germany stocks is significantly lower than that of the firm.
Moderna Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Moderna's current stock value. Our valuation model uses many indicators to compare Moderna value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Moderna competition to find correlations between indicators driving Moderna's intrinsic value. More Info.Moderna is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers reporting about 0.46 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Moderna is roughly 2.16 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moderna's earnings, one of the primary drivers of an investment's value.About Moderna Financial Statements
Moderna stakeholders use historical fundamental indicators, such as Moderna's revenue or net income, to determine how well the company is positioned to perform in the future. Although Moderna investors may analyze each financial statement separately, they are all interrelated. For example, changes in Moderna's assets and liabilities are reflected in the revenues and expenses on Moderna's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Moderna. Please read more on our technical analysis and fundamental analysis pages.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. MODERNA INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1800 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Moderna Stock
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out the analysis of Moderna Correlation against competitors. For more detail on how to invest in Moderna Stock please use our How to Invest in Moderna guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.